[New Times] With the introduction of Dihydroartemisinin-piperaquine (DHAP) and artesunate-pyronaridine (ASPY) on the list of anti-malarial drugs available in Rwanda, the number of treatments that can be transcribed for patients in the country has increased tremendously.
